ABBOTT LABORATORIES vs GILEAD SCIENCES, INC., two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where ABT and GILD diverge most: on operating margin, ABT reads 12.1% and GILD reads -133.2%; on net margin, ABT reads 13.9% and GILD reads -10.6%. The rest of the comparable metrics sit closer together. What ABT's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | ABT | GILD |
|---|---|---|
| Price | $101.97 | $143.76 |
| Market cap | $178.1B | $178.7B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | +10.3% | — |
| P/E | 28.6 | — |
| P/B | 3.38 | 15.11 |
| P/S | 3.95 | 5.87 |
| EV/EBITDA | 22.4 | 19.0 |
| Revenue growth | +6.6% | +5.6% |
| Operating margin | 12.1% | -133.2% |
| Net margin | 13.9% | -10.6% |
| Return on equity | 11.9% | -27.4% |
| Return on assets | 5.7% | -6.6% |
| Return on invested capital | 6.6% | 20.5% |
| FCF yield | 4.1% | 7.2% |
| Dividend yield | 2.4% | 2.2% |
| Debt / equity | 0.65 | 2.42 |
| Current ratio | 1.39 | 1.27 |
| Altman Z (solvency) | 7.16 | 6.06 |
| Piotroski F (quality) | 6 / 9 | 4 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.